Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B

Hepatology

Volumn 56, Issue 1, 2012, Pages 67-75

  Sonneveld, Milan J ^a   Rijckborst, Vincent ^a   Zeuzem, Stefan ^b   Heathcote, E Jenny ^c   Simon, Krzysztof ^d   Senturk, Hakan ^e   Pas, Suzan D ^a   Hansen, Bettina E ^a   Janssen, Harry L A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c UNIVERSITY OF TORONTO   (Canada)

^d WROCLAW MEDICAL UNIVERSITY   (Poland)

^e Bezmialem University   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2B; VIRUS DNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GENE DOSAGE; GENE FREQUENCY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NONHUMAN; PREDICTOR VARIABLE; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS CORE; VIRUS DETECTION; VIRUS MUTANT;

ADULT; BIOLOGICAL MARKERS; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; ODDS RATIO; POLYETHYLENE GLYCOLS; PROMOTER REGIONS, GENETIC; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VIRUS REPLICATION; YOUNG ADULT;

EID: 84863517149     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25636     Document Type: Article

References (31)

1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
2. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486-1500.
3. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539.
4. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-174.
5. Fattovich G, Olivari N, Pasino M, D'Onofrio M, Martone E, Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008; 57: 84-90.
6. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-129.
7. Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010; 139: 491-498.
8. Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 135: 459-467.
9. van Nunen AB, Hansen BE, Suh DJ, Lohr HF, Chemello L, Fontaine H, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003; 52: 420-424.
10. Wong VW, Wong GL, Yan KK, Chim AM, Chan HY, Tse CH, et al. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 1945-1953.
11. Senturk H, Baysal B, Tahan V, Zerdali H, Ozaras R, Tabak F, et al. Long-term effect of interferon therapy in patients with HBeAg positive chronic hepatitis B infection. Dig Dis Sci 2011; 56: 208-212.
12. Erhardt A, Reineke U, Blondin D, Gerlich WH, Adams O, Heintges T, et al. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 2000; 31: 716-725.
13. Frelin L, Wahlstrom T, Tucker AE, Jones J, Hughes J, Lee BO, et al. A mechanism to explain the selection of the hepatitis e antigen-negative mutant during chronic hepatitis B virus infection. J Virol 2009; 83: 1379-1392.
14. Ferns RB, Naoumov NV, Gilson RJ, Tedder RS. Presence of hepatitis B virus core promoter mutations pre-seroconversion predict persistent viral replication after HBeAg loss. J Clin Virol 2007; 39: 199-204.
15. Chu CM, Liaw YF. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology 2007; 133: 1458-1465.
16. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010; 52: 1251-1257.
17. Hussain M, Chu CJ, Sablon E, Lok AS. Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants. J Clin Microbiol 2003; 41: 3699-3705.
18. Pas SD, Fries E, De Man RA, Osterhaus AD, Niesters HG. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol 2000; 38: 2897-2901.
19. Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137: 2002-2009.
20. Sonneveld MJ, Rijckborst V, Cakaloglu Y, Simon K, Heathcote EJ, Tabak F, et al. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype. Antivir Ther 2012; 17: 9-17.
21. Pencina MJ, D'Agostino RBSr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med; 30: 11-21.
22. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335-352.
23. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
24. Chu CM, Yeh CT, Lee CS, Sheen IS, Liaw YF. Precore stop mutant in HBeAg-positive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAg-to-anti-HBe seroconversion. J Clin Microbiol 2002; 40: 16-21.
25. Chu CJ, Keeffe EB, Han SH, Perrillo RP, Min AD, Soldevila-Pico C, et al. Prevalence of HBV precore/core promoter variants in the United States. Hepatology 2003; 38: 619-628.
26. Tseng TC, Liu CJ, Wang CC, Chen PJ, Lai MY, Chen DS, et al. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels. Antivir Ther 2009; 14: 203-210.
27. Hou J, Schilling R, Janssen HL, Hansen BE, Heijtink R, Sablon E, et al. Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance. J Med Virol 2007; 79: 1055-1063.
28. Takeda K, Akahane Y, Suzuki H, Okamoto H, Tsuda F, Miyakawa Y, et al. Defects in the precore region of the HBV genome in patients with chronic hepatitis B after sustained seroconversion from HBeAg to anti-HBe induced spontaneously or with interferon therapy. Hepatology 1990; 12: 1284-1289.
29. Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008; 47: 428-434.
30. Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52: 454-461.
31. Pas SD, de Man RA, Fries E, Osterhaus AD, Niesters HG. The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine treatment as determined by reverse hybridisation. J Clin Virol 2002; 25: 63-71.